Pharmacoeconomics has been characterized as the depiction and examination of the cost of medication treatment to healthcare frameworks and society. All the more explicitly, pharmacoeconomic look into is the way toward recognizing, estimating, and contrasting the costs, dangers, and advantages of programs, services, or treatments and figuring out which elective delivers the best wellbeing result for the asset contributed. This data can help clinical chiefs in picking the most cost-effective treatment alternatives. Pharmacoeconomics is a division of results examine that can be utilized to measure the estimation of pharmaceutical care items and services. Pharmaceutical care has been characterized as the mindful arrangement of medication treatment for the reasons for accomplishing unequivocal results.
INTRODUCTION

Figure 1. Graphical Extract
Globally patients are affected by the high price of medicines. In many developing countries a high percentage of total health expenditure is financed by household out of-pocket expense. Many poor people frequently face a bitter decision between purchasing medication or buying such necessities as grocery and clothing due to limited resources and the high price of the prescription. Therefore, medication and drug therapy are an important matter to the society mainly those in need of medical services with limited financial resources. Human services costs have been expanding every year more than the normal rate of expansion. This proceeded with increment in costs has brought about a need to see how restricted assets can be utilized most productively and effectively.
Pharmacoeconomics role in many developing countries is in early stages with a limited knowledge of the subject matter. Therefore, lack of education and understanding of the topic is limiting the decision making by the health providers and health authorities.
Exhibit 1. Definitions of Selected Frequently Used
Pharmacoeconomic Analyses (Henry et.al., 2014) 
Type of Analysis Definition
Costeffectiveness
Comparison that balances a single unit of cost against a single unit of risks or benefits to the quality of life extended to the patient Costminimization
Comparison of multiple drugs of equal efficacy and equal tolerability to identify the least expensive therapy Cost-utility Ratio between the cost of a healthrelated intervention and the benefit. It produces in terms of number of years lived in full health Cost-benefit Determines whether an investment or policy decision is sound (justification/ feasibility) and provides a basis for evaluating policies by comparing the total Vol. 7, Issue 3 | pharmatutorjournal.com expected cost of each option against the total expected benefits to see whether the benefits outweigh the costs, and by how much; vaccination programs are a classic example
Statement of the problem
Pharmacoeconomics (PE) role in many developing countries is in early stages with a limited knowledge of the subject matter. Therefore, lack of education and understanding of the topic is limiting the decision making by the health providers and health authorities. Thereby, creating incapability in developing a plan for purchasing the maximum amount of benefits for a given resource use. Accordingly, unable to assist clinicians in choosing the most affordable options. Pharmacoeconomics and outcome research have a very significant function in medication expenditure management. Subsequently, healthcare moderateness has turned into a noteworthy issue in the lives of society and their prosperity. For this reason, understanding PE and the importance of its applications are vital in reducing healthcare wastage as explicit methodology, education, and initiative required for its progress.
The General Necessity of Pharmacoeconomics U.S. NHEA estimated health care spending grew 4% in 2017, reaching $3.5 trillion or $10,739 per person. As a share of the nation's GDP, health spending accounted for 18% (Web CMS). About 12% (over $900 per person) of health care expenditures were for medications in 2010. Health care costs have been increasing each year more than the average rate of inflation. CMC further realized aggregate healthcare spending would grow at a 5.8% average annual rate from 2015 to 2025, or 1.3% higher than the expected annual increase in the gross domestic product. This is causing more interest in new strategies across employers for drugs or administration. Increasing healthcare costs have forced employers to reassess the healthcare benefits they offer to employees (Vogenberg et.al., 2018) . This continued increase in costs has resulted in a need to understand how limited resources can be used most efficiently and effectively. Pharmacoeconomics is essential in several sectors such as 1. Healthcare industry in order to decide amongst precise research and development options. 2. Second, it is needed in government to determine program benefits and its operating expense. 3. The third area of need is in the private sector to facilitate the formulation of insurance benefits coverage. Basically, the PE is needful in following manner;  In Industry, it is useful in deciding among specific research and development alternatives.  In Government-Determining program benefits and prices paid and in Private Sector it can be used for designing insurance benefit coverage. 4. Additionally, it describes the economic relationship involving drug research, drug production, distribution, storage, pricing and its use by the society. It runs on the thread of our socioeconomic system, which regulates and influences all the sectors involved in pharmaceuticals (Gattani. Et.al., 2009 ).
PERSPECTIVES OF PHARMACO-ECONOMICS Patient
Perspective--Patient perspective is paramount because patients are the ultimate consumers of healthcare services. Costs from the viewpoint of patients are basically what patients pay for an item or administration-that is, the segment not secured by protection. Provider Perspective--Costs from the provider's perspective are the actual expense of providing a product or service, regardless of what the provider charges. Providers can be hospitals, MCOs, or private-practice physicians. From this perspective, direct costs such as drugs, hospitalization, laboratory tests, supplies, and salaries of healthcare professionals can be identified, measured, and compared. Payer Perspective--Payers include insurance companies, employers, or the government. From this perspective, costs represent the charges for healthcare products and services allowed or reimbursed by the payer. The primary cost for a payer is of a direct nature. However, indirect costs, such as lost workdays (absenteeism), being at work but not feeling well and therefore having lower productivity (presenteeism), also can contribute to the total cost of healthcare to the payer. Societal Perspective--Theoretically, all direct and indirect costs are included in an economic evaluation Vol. 7, Issue 3 | pharmatutorjournal.com Countries were classified into four levels. In level 1 (no PV), there are no legal or structural frameworks, no coordinated surveillance activities, and PV activities are not coordinated nationally. In level 2 (basic PV), policy and legal frameworks exist, institutions, guidelines, and procedures exist, and stakeholder roles are recognized albeit poorly coordinated. Additionally, the AE reporting system does not cover all sources of MRPs, signal generation and risk evaluation are poor, and the system lacks active signal evaluation and risk management. In level 3 (semi-functional PV), structural and organizational frameworks exist to collect and collate safety data and evaluate risks and benefits by passive and active surveillance. However, the countries lack risk management, risk prevention, and risk communication capacity. In level 4 (functional PV), a PV structure exists that permits passive and active surveillance, risk evaluation, risk communication, and regulatory action. Pharmacoeconomic data can support the inclusion or exclusion of a drug on or from the formulary and support practice guidelines that promote the most cost-effective or appropriate utilization of pharmaceutical products. Various strategies can be used to incorporate PE into formulary decision making.
Pharmacoeconomic Doctrine
In fact, the pharmacoeconomic assessment of formulary action is becoming a standardized part of many pharmacy and therapeutic (P&T) committee decision making process, when competing for hospital resources, PE can provide the data necessary that a pharmacy service maximizes the resources allocated to it by hospital administration.
Vol. 7, Issue 3 | pharmatutorjournal.com . Strict adherence to a formulary list alone will not improve treatment practice if drug selection is not based on STGs (i.e. if there is no consistency between the formulary list and the STGs). Furthermore, essential medicines can also be used inappropriately if there are no guidelines for disease management. Ideally, a formulary list should be developed after the appropriate treatment guidelines for common diseases have been identified or developed. In many countries, there are already national STGs and other texts on standard treatment protocols that can be followed and used as a starting point when developing a hospital formulary list or local STGs. Once a formulary list is established, a formulary manual, containing information on all the medicines in the formulary list, can be developed.
To Pharmacists:
Drug use evaluation is one of the important services provided by pharmacists. Ideally, that value should be translated into patient and financial outcomes. Apart from concentrating on inappropriately prescribed therapy and overprescribing, drug use evaluation focuses on the most cost-effective therapy. A high degree of sophistication is required in order to make such determination fairly, considering patient factors, disease factors, and other issues. Drug formulary services, Pharmacy and therapeutics committees are viewed as a means of reducing drug budgets and have had some value in encouraging drug therapy cost considerations, but they do not provide incentives to take into account overall medical costs, nor do they necessarily consider all consequences such as potential drug interactions, adverse reactions, and treatment response rates. Conducting cost-effectiveness studies allows an evaluation of total costs and consequences from various perspectives (Jo, 2014 Parameters influencing the successful uptake and integration of biosimilars into US oncology practices. The US FDA will provide a finalized pathway for biosimilar approval; this pathway will, in turn, influence the manufacturing and development process and the amount of clinical data needed for approval. The efficacy and safety of biosimilars will be monitored via ongoing pharmacovigilance practices to ensure that potential immunogenicity or adverse events with a given biosimilar can be identified quickly and addressed. Biosimilars have the potential to offer cost-savings with comparable efficacy and safety to innovator products. They are being used in the European Union, Canada, Japan, and Australia and may help with improving health outcomes while minimizing costs to patients and global healthcare systems. The overall value of a biosimilar is not determined solely by its pricing. Efficacy and safety relative to the reference biologic drug and competitive agents as well as development and manufacturing costs, treatment administration costs, and results from longterm safety monitoring are considered (Source: Henry et.al., 2014).
Pharmacoeconomic studies find value in  Fixing the price of a new drug and re-fixing the price of an existing drug  Finalizing a drug formulary  Creating data for promotional materials of medicines.  Compliance of requirement for drug license. 
PHARMACOECONOMIC COMPONENTS A. Cost of drug
Cost is defined as the value of the resources consumed a drug therapy of interest. It is the amount paid to the suppliers by the patient. Consequence is defined as the effects, outputs, or outcomes of the program of drug therapy of interest.
Direct medical cost:
This is what is paid for specialized health resources and services. It includes the physician's salaries; the acquisition cost of medicine; consumables associated with drug administration; staff time in preparation and administration of medicines; laboratory costs of monitoring for effectiveness and adverse drug reactions. Direct non-medical cost: This includes cost necessary to enable an individual receive medical care such as lodging, special diet and transportation; lost work time (important to employers) such as acute Otitis media in pediatric patients with professional parents who lost work time during the treatment of their kid. Indirect cost: This is the cost incurred by the patient, family, friends or society. Many of these are difficult to measure, but should be of concern to society as a whole. This includes productivity loss in the society; unpaid care givers; lost wages; expenses of illness borne by patients, relatives, friends, employers and the government and; loss of leisure time. Intangible costs: These are costs related with the patient's pain and suffering; worry and other distress of the family members of a patient; effect on quality of life and health perceptions. For example, patients of rheumatoid arthritis, cancer or having terminal illnesses in which quality of life is suffered due to adverse reactions of the drug treatment. These are difficult to measure in monetary terms but represent a considerable concern for both doctors and patients. Quality adjusted life year (QALY) is one method by which intangible costs can be effectively integrated in PE analysis.
The cost can be measured in following ways: . As significant progress was made in recent years and there are many alternative treatments, which are indicated according to the stage and the type of the disease, the age and health status of patient, and vary from surgery to hormonal treatment and chemotherapy. Time horizon, stage of the disease, patient age, therapy onset, benefit duration and time to recurrence may influence the results. Pharmacoeconomic analyses of alternative therapy options will improve decision-making and will help to optimize the use of scarce health care resources allocated to the patient care. Costs involved in pharmacoeconomic evaluation can be mainly divided into financial cost (mandatory cost) and economic cost (resource for which no mandatory payment is made) opportunity cost is the benefit foregone when selecting one therapy alternative over the next best alternative. Several costs can be measured when weighing up the cost of any invention. The first step in any cost analysis is identification of the various costs. These can be direct, indirect and intangible.
ECONOMIC EVALUATION METHODS
A. Cost-of-Illness Evaluation A cost-of-illness (COI) evaluation identifies and estimates the overall cost of a particular disease for a defined population. This evaluation method is often referred to as burden of illness and involves measuring the direct and indirect costs attributable to a specific disease. The costs of various diseases, including diabetes, mental disorders, and cancer, in the United States have been estimated. By successfully identifying the direct and indirect costs of an illness, one can determine the relative value of a treatment or prevention strategy. For example, by determining the cost of a particular disease to society, the cost of a prevention strategy could be subtracted from this to yield the benefit of implementing this strategy nationwide. COI evaluation is not used to compare competing treatment alternatives but to provide an estimation of the financial burden of a disease. Thus, the value of prevention and treatment strategies can be measured against this illness cost.
B. Cost-Minimization Analysis
Cost-minimization analysis (CMA) involves the determination of the least costly alternative when comparing two or more treatment alternatives. With CMA, the alternatives must have an assumed or demonstrated equivalency in safety and efficacy (i.e., the two alternatives must be equivalent therapeutically). Once this equivalency in outcome is confirmed, the costs can be identified, measured, and compared in monetary units (dollars). CMA is a relatively straightforward and simple method for comparing competing programs or treatment alternatives as long as the therapeutic equivalence of the alternatives being compared has been established. If no evidence exists to support this, then a more comprehensive method such as cost-effectiveness analysis should be employed. Remember, CMA shows only a "cost savings" of one program or treatment over another. Employing CMA is appropriate when comparing two or more therapeutically equivalent agents or alternate dosing regimens of the same agent. This method has been used frequently, and its application could expand given the increasing number of "me too" products and generic competition in the pharmaceutical market. measurement, and comparison of the benefits and costs of a program or treatment alternative. Both the costs and the benefits are measured and converted into equivalent dollars in the year in which they will occur. The CBA is also defined as a systematic process for calculating and comparing benefits and costs of a project, decision or government policy (hereafter, "project"). Broadly, CBA has two purposes: 1. To determine if it is a sound investment/ decision (justification/ feasibility) 2. To provide a basis for comparing projects. It involves comparing the total expected cost of each option against the total expected benefits, to see whether the benefits outweigh the costs, and by how much.
C. Cost-Benefit Analysis
CBA is related to, but distinct from cost-effectiveness analysis. In CBA, benefits and costs are expressed in monetary terms, and are adjusted for the time value of money, so that all flows of benefits and flows of project costs over time (which tend to occur at different points in time) are expressed on a common basis in terms of their "net present value." 
PHARMACOECONOMIC EVALUATION STEPS
Pharmacoeconomic evaluation process contained several necessary steps useful in the health care system and nearly any therapeutic area or healthcare service.
Define the problem:
A general question might be, "which antiemetic regimen represents the best value for the prevention of chemotherapyinduced emesis (CIE)?" However, a more succinct and measurable the problem would be "which regimen is the best value for preventing acute CIE patients receiving highly emetogenic chemotherapy?"
Gather various functional team members:
Team members differ contingent on the analysis but may include members from medicine, nursing, pharmacy, hospital administration, and information technology and systems. 3. Define the perspective: Choose a study perception typically pertinent to the problem. For example, if the problem is similar as given in
Step 1, then the institution or health care system perspective is a most appropriate chosen alternative.
Identify therapeutic preferences and outcomes:
Treatment options include pharmacologic and non-pharmacologic choices. However, it should comprise all clinically relevant options. The identified outcomes should consist of both positive and negative clinical outcomes.
Determine the applicable pharmacoeconomic method:
The methods of Pharmacoeconomic to choose from are CMA, CBA, CEA, and CUA. Employing the incorrect method can adversely affect medication decisions influencing both costs Moreover, quality of care.
Set a financial value on treatment alternatives
and outcomes: Employing a financial value on treatment options and outcomes for drug administration and cost of purchase as well as the cost of positive and negative medical results. 7. Pinpoint resources to implement evaluation in a proficient method: Depending on the study, the necessary resources will fluctuate. However, it possibly will comprise entrance to medical or computerized records, regular medical personnel salaries specifically medical staff. 8. Detect possibilities that outcomes can transpire in the population under study: What are the likelihoods of the results recognized in step 4 (e.g. identifying therapeutic preferences and outcome) in fact to occur practically? By means of principal literature and professional selection, these probabilities can be acquired and perhaps expressed by way of efficacy rates and occurrence of ADRs. 9. Implement decision analysis: Numerous economic evaluations can be conducted by utilizing decision analysis, including CEA. Even though, Decision analysis and decision tree may not require forever evaluations in PE. However, they provide firm support for the verdict at Vol. 7, Issue 3 | pharmatutorjournal.com hand. Using a decision tree, treatment options, results, and probabilities presented explicitly. Additionally, it can reduce algebraically to a single value for comparison (i.e., CEA ratio). 10. Discount costs, sensitivity, incremental cost analysis: Prospecting costs and consequences discounted back to their present value. Furthermore, sensitive variables tested over a clinically related range, and outcomes recalculated. If applicable, an incremental analysis of the costs and consequences should be made.
Present the outcome of study:
The study results presented to the cross-functional team and the proper committees. 12. Cultivate a policy and procedure for intervention: Exploit the study outcomes and develop a policy and an intervention for the enhancement of healthcare quality and maintain efficiency.
Implement policy and educate professionals:
Devote sufficient time and resources are cleverly executing the policy or intervention. Moreover, the healthcare professionals affected by the policy must be educated using different strategies such as verbal, written and online communication technology. 14. Follow-up documentation: Monitoring collected data after the implementation of policy and intervention for a practical period as this information will offer a response to the achievement and quality of the policy or intervention ( 
Pharmacoeconomics -A Tool for Pharmacists
PE helps us to make decisions about the use of medicines. Most pharmacoeconomic studies in health care are cost-effectiveness studies set out to demonstrate how to achieve an objective with the least use of resources. This should not be confused with efficiency, which measures how well we use resources in order to obtain the desired outcome.
Vol. 7, Issue 3 | pharmatutorjournal.com  The basis of financing secondary care is currently changing. Under "payment by results", providers of care are paid for each patient spell according to a national tariff, which is based on a national average cost for a particular patient spell. As foundation trusts increase, the number of hospitals that depend on tariff payments for their income also grows. Therefore, using the most efficient methods of working to reduce cost and maximize benefits is becoming increasingly important.  PE is part of the tool bag pharmacists can use to improve the efficiency of their hospital. In theory, if hospitals improve their efficiency and deliver increased activity the trust will make a profit, which should then be invested in improving health care. In some medical disciplines the medicines element to the overall tariff price can be considerable, and savings on costs of medicines can make the difference between a profit and loss for the trust.  The application of PE to improve the efficient use of medicines is a key component in this productivity drive. Although the clinical role of the profession is appreciated, it is the role of the pharmacist in advising on medicines expenditure and ensuring economical use of medicines that has increased demand for their services. CONCLUSION PE evaluation has become an important area of interest to find the optimal therapy at the lowest price as healthcare resources are not easily accessible and affordable to many patients. Numerous drug alternatives and empowered consumers also fuel the need for economic evaluations of pharmaceutical products. In developing countries, the PE can help the poor and middle class to obtain well health care services because many households are below poverty line, unaffordable for private health care. Costs of the medicines are constantly growing. In countries with scarce resources and an ever-growing population with diverse health care needs, an innovative method called, pharmacoeconomic evaluation plays an essential role in determining the delivery of reasonable and cost-effective health services. Applied PE has been lacking as the most vital practice of pharmacy. Understanding the principles, methods, and application of PE, enables pharmacists to make healthier, more informed judgments concerning the use of pharmaceutical goods and services. Specifically, decisions that ultimately represent the best welfares of the patient, the healthcare system, and society. PE applied to any therapeutic area like hospital pharmacy, using a variety of application plans.
